search
Back to results

STIMO: Epidural Electrical Simulation (EES) With Robot-assisted Rehabilitation in Patients With Spinal Cord Injury. (STIMO)

Primary Purpose

Spinal Cord Injury

Status
Active
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Device implantation
Sponsored by
Jocelyne Bloch
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Spinal Cord Injury focused on measuring Spinal Cord Injury, Epidural Electrical Stimulation, Robot-assisted

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-65 (women or men)
  • Incomplete SCI graded as AIS A,B,C & D
  • Level of lesion: T10 and above, based on AIS level determination by the PI, with preservation of conus function
  • The intact distance between the cone and the lesion must be at least 60mm
  • Focal spinal cord disorder caused by either trauma or epidural, subdural or intramedullary bleeding
  • Minimum 12 months post-injury
  • Completed in-patient rehabilitation program
  • Able to stand with walker or 2 crutches
  • Stable medical and physical condition as considered by Investigators
  • Adequate care-giver support and access to appropriate medical care in patient's home community
  • Agree to comply in good faith with all conditions of the study and to attend all required study training and visits
  • Must participate in two training sessions before enrolment
  • Must provide and sign Informed Consent prior to any study related procedures

Exclusion Criteria:

  • Limitation of walking function based on accompanying (CNS) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders)
  • History of significant autonomic dysreflexia
  • Cognitive/brain damage
  • Epilepsy
  • Patient who has spinal canal stenosis
  • Patient who uses an intrathecal Baclofen pump.
  • Patient who has any active implanted cardiac device such as pacemaker or defibrillator.
  • Patient who has any indication that would require diathermy.
  • Patient who has any indication that would require MRI.
  • Patient that have an increased risk for defibrillation
  • Severe joint contractures disabling or restricting lower limb movements.
  • Haematological disorders with increased risk for surgical interventions (increased risk of haemorrhagic events).
  • Participation in another locomotor training study.
  • Congenital or acquired lower limb abnormalities (affection of joints and bone).
  • Women who are pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding or not willing to take contraception.
  • Known or suspected non-compliance, drug or alcohol abuse.
  • Spinal cord lesion due to either a neurodegenerative disease or a tumour.
  • Patient has other anatomic or co-morbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results.
  • Patient is unlikely to survive the protocol follow-up period of 12 months.

Sites / Locations

  • Centre Hospitalier Universitaire Vaudois

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

All patients

Arm Description

Patients will participate during 8-12 months, during which there will be : Pre-implant evaluations (6-8 weeks) Device implantation and stimulation optimization (6-8 weeks) Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system. An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system.

Outcomes

Primary Outcome Measures

Safety and Preliminary efficacy: Walking Index for Spinal Cord Injury (WISCI II)
The Walking Index for Spinal Cord Injury is an ordinal scale that has been frequently used in clinical trials as a tool to assess walking function.
Safety and Preliminary efficacy: 10-Meter Walk Test (10MWT)
10-Meter Walk Test (10MWT) is commonly used to measure walking speeds during two conditions: comfortable and fast. It yields scores that are valid and reliable for SCI individuals.
Safety and Preliminary efficacy: Weight Bearing Capacity (WBC).
Weight-bearing capacity (WBC) is an important outcome to monitor and particularly relevant in patients with severe motor impairments who cannot walk independently.

Secondary Outcome Measures

Improvement of walking capability: Spinal Cord Independence Measure (SCIM III).
Spinal Cord Independence Measure (SCIM III) is a test used as a reference tool for the assessment of overall functional ability after SCI.
Improvement of walking capability: 6-Min Walk Test (6MWT).
This assessment is a submaximal test that will be used as a global and easy indicator of the locomotor performance.

Full Information

First Posted
October 12, 2016
Last Updated
October 16, 2023
Sponsor
Jocelyne Bloch
Collaborators
Ecole Polytechnique Fédérale de Lausanne, Foundation Wings For Life
search

1. Study Identification

Unique Protocol Identification Number
NCT02936453
Brief Title
STIMO: Epidural Electrical Simulation (EES) With Robot-assisted Rehabilitation in Patients With Spinal Cord Injury.
Acronym
STIMO
Official Title
Efficacy of Spinal Epidural Electrical Stimulation (EES) in Combination With Robot-assisted Neurorehabilitation in Patients With Spinal Cord Injury (STIMO)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 2016 (Actual)
Primary Completion Date
July 2026 (Anticipated)
Study Completion Date
July 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jocelyne Bloch
Collaborators
Ecole Polytechnique Fédérale de Lausanne, Foundation Wings For Life

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
STIMO is a First-in-Man (FIM) study to confirm the safety and feasibility of a closed-loop Epidural Electrical Stimulation (EES) in combination with overground robot assisted rehabilitation training for patients with chronic incomplete spinal cord injury (SCI). Patients will participate during 8-12 months, during which there will be: Pre-implant evaluations (6-8 weeks) Device implantation and stimulation optimization (6-8 weeks) Overground rehabilitation training with EES (5-6 months). In the period after implantation, participants need to be present for testing and training, 4 days per week at the CHUV University Hospital in Lausanne (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with training outside the rehabilitation room by making use of the Home-use system. At the end of the protocol, the study aims to make the patients walk better and faster. As this is the first study of its kind, success is not guaranteed. However, the potential benefits outweigh the potential risks. An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system.
Detailed Description
STIMO is a First-in-Man (FIM) study with the objective to confirm the safety and feasibility of a closed-loop Epidural Electrical Stimulation (EES) in combination with overground robot assisted rehabilitation training for patients with chronic incomplete spinal cord injury (SCI), as it was previously successfully demonstrated in animals. The study consists of two phases: A. Main study The main study lasts about 8-12 months for each individual participant, from signing informed consent to the final test in the study This period can be divided into 3 distinct phases: Pre-implant : about 6-8 weeks from informed consent to implant. During this phase, patient will participate during a total of 6 distinct days of evaluations, of which 5 days in Lausanne and 1 day at the assessment center in Zurich. The patient will also participate to 3 weeks of pre-implantation training in a Body Weight Support (BWS) system. Implant and stimulation optimization: about 6-8 weeks, including the implantation of the epidural lead and the neurostimulator. In this phase, the optimal stimulation parameters will be determined for the flexing and stretching of both legs. During this period, participants need to be present at the CHUV University Hospital in Lausanne 4-5 days per week (lodging can be provided). Rehabilitation training and final evaluation: 4 days per week of rehabilitation training during a period of 5 months, followed by a final evaluation lasting 4 days in Lausanne and 1 day in Zurich. In this phase, the patients receive intensive overground rehabilitation training using a body weight support device in combination with EES, with the aim of significantly improving their walking capabilities. During this period, participants need to be present at the CHUV University Hospital in Lausanne (lodging can be provided) 4 days per week. Once the patient has shown the ability to stand or walk safely without robotic assistance, he/she is offered the possibility to complement his/her neuro-rehabilitative training using EES outside the robotic environment and rehabilitation room by making use of the Home-use system. B. Optional study extension (3 years) The patient has the possibility to continue his/her neuro-rehabilitative training with the home-use system for an additional period of 3 years after the end of clinical rehabilitation period. During this period, evaluation measures and technical check-ups are made at regular time points. The patient is contacted monthly to ensure a normal training conduct and a safety follow-up. At the end of the protocol, the study aims to make the patients walk better and faster. Improvements are quantified through pre-defined measures assessed prior to implant and at the end of the main study as well as at regular time points during the optional study extension. As this is the first study of its kind, success is not guaranteed. However, the potential benefits outweigh the potential risks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injury
Keywords
Spinal Cord Injury, Epidural Electrical Stimulation, Robot-assisted

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
All patients
Arm Type
Experimental
Arm Description
Patients will participate during 8-12 months, during which there will be : Pre-implant evaluations (6-8 weeks) Device implantation and stimulation optimization (6-8 weeks) Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system. An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system.
Intervention Type
Procedure
Intervention Name(s)
Device implantation
Intervention Description
Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space Implantation of Activa RC neurostimulator
Primary Outcome Measure Information:
Title
Safety and Preliminary efficacy: Walking Index for Spinal Cord Injury (WISCI II)
Description
The Walking Index for Spinal Cord Injury is an ordinal scale that has been frequently used in clinical trials as a tool to assess walking function.
Time Frame
7 months after implant
Title
Safety and Preliminary efficacy: 10-Meter Walk Test (10MWT)
Description
10-Meter Walk Test (10MWT) is commonly used to measure walking speeds during two conditions: comfortable and fast. It yields scores that are valid and reliable for SCI individuals.
Time Frame
7 months after implant
Title
Safety and Preliminary efficacy: Weight Bearing Capacity (WBC).
Description
Weight-bearing capacity (WBC) is an important outcome to monitor and particularly relevant in patients with severe motor impairments who cannot walk independently.
Time Frame
7 months after implant
Secondary Outcome Measure Information:
Title
Improvement of walking capability: Spinal Cord Independence Measure (SCIM III).
Description
Spinal Cord Independence Measure (SCIM III) is a test used as a reference tool for the assessment of overall functional ability after SCI.
Time Frame
7 months after implant
Title
Improvement of walking capability: 6-Min Walk Test (6MWT).
Description
This assessment is a submaximal test that will be used as a global and easy indicator of the locomotor performance.
Time Frame
7 months after implant
Other Pre-specified Outcome Measures:
Title
ASIA Impairment Scale (AIS)
Description
The American Spinal Injury Association (ASIA) Standard Neurological Classification of Spinal Cord Injury is a standard method of assessing the neurological status, including motor and sensory evaluations, of a person who has sustained a spinal cord injury.
Time Frame
7 months after implant
Title
Modified Ashworth Scale (MAS)
Description
The Modified Ashworth Scale is a method for measuring muscle spasticity. It involves manual movement of a limb through its range of motion to passively stretch specific muscle groups.
Time Frame
7 months after implant
Title
Berg Balance Scale (BBS)
Description
The Berg Balance Scale was developed to measure balance among frail populations with impairment in balance function by assessing the performance of functional tasks with a 14-item scale.
Time Frame
7 months after implant
Title
Quality of life (pain, spasticity, bladder/bowel regulation, sex life and sleep)
Description
A dedicated set of questionnaires is selected to monitor the quality of life (QoL). The questionnaires are dedicated to the social participation to society as well as to the self-reported problems affecting the QoL of SCI individuals (pain, spasticity, bladder/bowel regulation, sex life and sleep).
Time Frame
7 months after implant
Title
Neurobiomechanical recordings
Description
Neurobiomechanical behaviour during different locomotor tasks will be recorded with a combination of kinematics, kinetics and EMG data.
Time Frame
7 months after implant
Title
Electrophysiological recordings and voluntary control of muscle contraction
Description
A dedicated set of tests is selected to assess a variety of physiological parameters.
Time Frame
7 months after implant
Title
Short Pain Assessment
Description
The pain assessment reports on the subjective feeling of pain during the previous week. It assesses the nature and location of pain and its interference with activities of daily living (ADL).
Time Frame
7 months after implant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-65 (women or men) Incomplete SCI graded as AIS A,B,C & D Level of lesion: T10 and above, based on AIS level determination by the PI, with preservation of conus function The intact distance between the cone and the lesion must be at least 60mm Focal spinal cord disorder caused by either trauma or epidural, subdural or intramedullary bleeding Minimum 12 months post-injury Completed in-patient rehabilitation program Able to stand with walker or 2 crutches Stable medical and physical condition as considered by Investigators Adequate care-giver support and access to appropriate medical care in patient's home community Agree to comply in good faith with all conditions of the study and to attend all required study training and visits Must participate in two training sessions before enrolment Must provide and sign Informed Consent prior to any study related procedures Exclusion Criteria: Limitation of walking function based on accompanying (CNS) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders) History of significant autonomic dysreflexia Cognitive/brain damage Epilepsy Patient who has spinal canal stenosis Patient who uses an intrathecal Baclofen pump. Patient who has any active implanted cardiac device such as pacemaker or defibrillator. Patient who has any indication that would require diathermy. Patient who has any indication that would require MRI. Patient that have an increased risk for defibrillation Severe joint contractures disabling or restricting lower limb movements. Haematological disorders with increased risk for surgical interventions (increased risk of haemorrhagic events). Participation in another locomotor training study. Congenital or acquired lower limb abnormalities (affection of joints and bone). Women who are pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding or not willing to take contraception. Known or suspected non-compliance, drug or alcohol abuse. Spinal cord lesion due to either a neurodegenerative disease or a tumour. Patient has other anatomic or co-morbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results. Patient is unlikely to survive the protocol follow-up period of 12 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Grégoire Courtine
Organizational Affiliation
Ecole Polytechnique Fédérale de Lausanne
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Armin Curt
Organizational Affiliation
University Hospital Balgrist, Zuerich
Official's Role
Study Chair
Facility Information:
Facility Name
Centre Hospitalier Universitaire Vaudois
City
Lausanne
State/Province
Canton De Vaud
ZIP/Postal Code
1011
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
24713270
Citation
Angeli CA, Edgerton VR, Gerasimenko YP, Harkema SJ. Altering spinal cord excitability enables voluntary movements after chronic complete paralysis in humans. Brain. 2014 May;137(Pt 5):1394-409. doi: 10.1093/brain/awu038. Epub 2014 Apr 8. Erratum In: Brain. 2015 Feb;138(Pt 2):e330.
Results Reference
background
PubMed Identifier
22653117
Citation
Dominici N, Keller U, Vallery H, Friedli L, van den Brand R, Starkey ML, Musienko P, Riener R, Courtine G. Versatile robotic interface to evaluate, enable and train locomotion and balance after neuromotor disorders. Nat Med. 2012 Jul;18(7):1142-7. doi: 10.1038/nm.2845.
Results Reference
background
PubMed Identifier
21601270
Citation
Harkema S, Gerasimenko Y, Hodes J, Burdick J, Angeli C, Chen Y, Ferreira C, Willhite A, Rejc E, Grossman RG, Edgerton VR. Effect of epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study. Lancet. 2011 Jun 4;377(9781):1938-47. doi: 10.1016/S0140-6736(11)60547-3. Epub 2011 May 19.
Results Reference
background
PubMed Identifier
22654062
Citation
van den Brand R, Heutschi J, Barraud Q, DiGiovanna J, Bartholdi K, Huerlimann M, Friedli L, Vollenweider I, Moraud EM, Duis S, Dominici N, Micera S, Musienko P, Courtine G. Restoring voluntary control of locomotion after paralyzing spinal cord injury. Science. 2012 Jun 1;336(6085):1182-5. doi: 10.1126/science.1217416.
Results Reference
background
PubMed Identifier
25253676
Citation
Wenger N, Moraud EM, Raspopovic S, Bonizzato M, DiGiovanna J, Musienko P, Morari M, Micera S, Courtine G. Closed-loop neuromodulation of spinal sensorimotor circuits controls refined locomotion after complete spinal cord injury. Sci Transl Med. 2014 Sep 24;6(255):255ra133. doi: 10.1126/scitranslmed.3008325.
Results Reference
background
PubMed Identifier
26779815
Citation
Wenger N, Moraud EM, Gandar J, Musienko P, Capogrosso M, Baud L, Le Goff CG, Barraud Q, Pavlova N, Dominici N, Minev IR, Asboth L, Hirsch A, Duis S, Kreider J, Mortera A, Haverbeck O, Kraus S, Schmitz F, DiGiovanna J, van den Brand R, Bloch J, Detemple P, Lacour SP, Bezard E, Micera S, Courtine G. Spatiotemporal neuromodulation therapies engaging muscle synergies improve motor control after spinal cord injury. Nat Med. 2016 Feb;22(2):138-45. doi: 10.1038/nm.4025. Epub 2016 Jan 18.
Results Reference
background
PubMed Identifier
35132264
Citation
Rowald A, Komi S, Demesmaeker R, Baaklini E, Hernandez-Charpak SD, Paoles E, Montanaro H, Cassara A, Becce F, Lloyd B, Newton T, Ravier J, Kinany N, D'Ercole M, Paley A, Hankov N, Varescon C, McCracken L, Vat M, Caban M, Watrin A, Jacquet C, Bole-Feysot L, Harte C, Lorach H, Galvez A, Tschopp M, Herrmann N, Wacker M, Geernaert L, Fodor I, Radevich V, Van Den Keybus K, Eberle G, Pralong E, Roulet M, Ledoux JB, Fornari E, Mandija S, Mattera L, Martuzzi R, Nazarian B, Benkler S, Callegari S, Greiner N, Fuhrer B, Froeling M, Buse N, Denison T, Buschman R, Wende C, Ganty D, Bakker J, Delattre V, Lambert H, Minassian K, van den Berg CAT, Kavounoudias A, Micera S, Van De Ville D, Barraud Q, Kurt E, Kuster N, Neufeld E, Capogrosso M, Asboth L, Wagner FB, Bloch J, Courtine G. Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis. Nat Med. 2022 Feb;28(2):260-271. doi: 10.1038/s41591-021-01663-5. Epub 2022 Feb 7.
Results Reference
derived
Links:
URL
http://courtine-lab.epfl.ch/
Description
Courtine-Lab is a part of the Center for Neuroprosthetic and Brain Mind Institute of the Life Science School at the Swiss Federal Institute of Technology Lausanne (EPFL). The laboratory is headed by Professor Grégoire Courtine.

Learn more about this trial

STIMO: Epidural Electrical Simulation (EES) With Robot-assisted Rehabilitation in Patients With Spinal Cord Injury.

We'll reach out to this number within 24 hrs